Restoring ciliary function to differentiated primary ciliary dyskinesia cells with a lentiviral vector

Area of Science:

• Genetics
• Cell Biology
• Respiratory Medicine

Background:

• Primary ciliary dyskinesia (PCD) is a genetic disorder affecting ciliary function and mucociliary clearance.
• Mutations in the Dnaic1 gene disrupt ciliary activity in mouse models, leading to lung disease.
• Current treatments for PCD are limited, necessitating the exploration of novel therapeutic strategies.

Purpose of the Study:

• To investigate the potential of gene replacement therapy for treating primary ciliary dyskinesia (PCD).
• To assess the efficacy of lentiviral gene transfer in restoring Dnaic1 expression and ciliary function in mouse models of PCD.
• To determine the minimum level of restored ciliary activity required to prevent disease development.

Main Methods:

• Utilized lentiviral vectors to deliver the Dnaic1 gene to cultured mouse tracheal cells and in vivo models.
• Assessed gene transfer efficiency and restoration of ciliary activity in Dnaic1-deficient cells and mice.
• Administered tamoxifen to Dnaic1(flox/flox) mice to induce gene recombination and evaluated disease prevention.

Main Results:

• Lentiviral gene transfer successfully restored Dnaic1 expression and ciliary activity in cultured Dnaic1(-/-) mouse cells.
• Apical application of lentiviral vectors demonstrated effective gene transfer to differentiated cells.
• Restoration of approximately 20% of ciliary activity in vivo was sufficient to prevent rhinosinusitis development.
• Severe rhinitis in Dnaic1(-/-) mice impeded efficient gene transfer, highlighting a challenge for therapeutic application.

Conclusions:

• Gene replacement therapy is a potential treatment for primary ciliary dyskinesia.
• Further optimization of gene transfer methods is crucial for clinical success in PCD patients.
• The study provides a foundation for developing advanced gene therapy approaches for PCD.